...
首页> 外文期刊>Human Pathology >Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma
【24h】

Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma

机译:中期因子的强免疫表达与BRAFV600E甲状腺乳头状癌多发淋巴结转移有关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Midkine is a multifunctional, heparin-binding growth factor that is frequently expressed in patients with malignancies but is undetectable in healthy adults. In various cancers, high expression of midkine is associated with aggressive clinical behavior and a poor prognosis. In the present study, we investigated the expression of midkine in papillary thyroid carcinoma (PTC) and assessed its association with a BRAFV600E mutation and the clinicopathological parameters. We determined the presence of a BRAFV600E mutation in 79 cases of PTC and examined the effects of the BRAFV600E mutation on midkine expression in primary thyrocytes. In addition, we evaluated the association between midkine expression and various clinicopathological parameters. We found that midkine is more frequently expressed in BRAFV600E PTC (68.3%) than in BRAF wild-type PTC (18.8%). BRAFV600E transduction could up-regulate midkine expression in primary thyrocytes. Moreover, midkine expression was associated with multiple lymph node (>= 5) metastases in BRAFV600E PTC. In conclusion, our results suggest that midkine expression could be a clinically useful marker in predicting the presence of multiple lymph node metastases in BRAFV600E PTC. (C) 2015 Elsevier Inc. All rights reserved.
机译:Midkine是一种多功能的肝素结合生长因子,在恶性肿瘤患者中经常表达,而在健康成年人中则无法检测到。在各种癌症中,midkine的高表达与侵略性临床行为和不良预后有关。在本研究中,我们调查了中期因子在甲状腺乳头状癌(PTC)中的表达,并评估了其与BRAFV600E突变和临床病理参数的关系。我们确定了BRAFV600E突变在79例PTC中的存在,并检查了BRAFV600E突变对原代甲状腺细胞中中期因子表达的影响。此外,我们评估了中期因子表达与各种临床病理参数之间的关联。我们发现,BRAFV600E PTC中midkine的表达更高(68.3%),而BRAF野生型PTC中的midkine的表达更高(18.8%)。 BRAFV600E转导可能上调原代甲状腺细胞中中期因子的表达。此外,BRAFV600E PTC中中期因子的表达与多处淋巴结转移(> = 5)有关。总之,我们的结果表明,中期因子表达可能是预测BRAFV600E PTC中多个淋巴结转移的临床有用标志物。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号